An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

A nurse practitioner discusses how breast cancer treatment can impact sexual health, and how nurses and APPs can guide ...

With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.

Research is analyzing the effect of imtermittent fasting on quality of life outcomes in patients undergoing radiation therapy ...

October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

You can control where you focus your attention,” said Anne M. Reb, PhD, NP, who recently presented on a nurse-led ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain ...

Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or ...

While pregnancy-associated cancer risks increased with age, breast cancer during pregnancy tended to not impact obstetric ...

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.